Ng and BACE1 are both linked to attractive drug targets in Alzheimer’s disease, but treatment trials have failed to demonstrate positive effects on disease progression.26,35 While increased Ng and BACE1 levels are linked to Alzheimer’s disease pathology and symptoms, they are differentially expressed between patients. This evidence concerns the gene BACE1 and early-onset autosomal dominant Alzheimer disease.